Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 16/20 | 0.64 |
| ▸ | MAOA | P21397 | 1/20 | 0.64 |
| ▸ | GRM5 | P41594 | 9/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.49 |
| ▸ | RELA | Q04206 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628149 | 0.89 | MAOB (0.51) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL16789730 | 0.85 | MAOB (0.50) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL4728838 | 0.79 | MAOB (0.66) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL569174 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL86965 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL1091999 | 0.78 | MAOB (1.00) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL4726346 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL8578811 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL768839 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 | |
| SCHEMBL14981170 | 0.78 | MAOB (0.64) | MAOBMAOAGRM5NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | USA Elixiria Biotech Inc. (US) | 2023-10-12 | — | — | US | disclosed |
| EP-2245027-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322692-A1 | COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF | PPARA, PPARG, PPARD | MAOB 1632/4885MAOA 1423/4885GRM5 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.